{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Statistical Analyses:', 'Study endpoints will be evaluated for all subjects from Baseline to Week 24the EOT Visit.', 'Primary Efficacy Endpoint', 'The primary outcome measure is the effect of teprotumumab on the proptosis responder rate at', 'Week 24 the EOT Visit.', 'Secondary Efficacy Endpoints', 'Secondary efficacy endpoints include the percentage of subjects with a CAS value of 0 or 1 at', 'Week 24, the EOT Visit, and the-mean change from Baseline to Week 24 the EOT Visit in the', '\"study eye\" proptosis measurement, diplopia responder rate at Week 24, and mean change', 'from Baseline to Week 24 in the-GO-QoL questionnaire overall score.', 'Exploratory Efficacy Endpoints', 'Week 24 EOT-data will be summarized for the overall responder rate, the Clinical Measures of', 'Severity individual response status frequencies, the percentage of responders for each component', 'of the Clinical Measures of Severity, and the overall responder rate stratified by the level of', 'response. Mean changes from Baseline to Week 24 the EOT Visit-will be summarized for the', 'CAS, the GO-QoL questionnaire VF and A subscale scores, and the motility component of the', 'Clinical Measures of Severity. PK parameters will be summarized.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 10 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '2.1', 'Schedule of Assessments', 'Open-Label Treatment Period 1', 'Follow-Up Period', 'Follow-Up Contact 3', '(24 Weeks)', '2', '(24 weeks)', '(48 Weeks)', '11/', 'FU3/', 'Study Visit', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'PWEO', 'FU1', 'FU2', 'FU4', 'FU5', 'FU4', 'FU5', 'PWEOS', 'T4', 'Week (W)/', 'Day 16', 'W1', 'W3', 'W4/', 'W6', 'W9', 'W12/', 'W15', 'W18', 'W21', 'W24/', 'W28/', 'W36/', 'W48/', 'W48/', 'W72/', 'W72/', 'W96/', 'Month (M)', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M12', 'M18', 'M18', 'M24', 'Visit Window ( days)', '(+14)7', '(+1)', '(+3)', '(+1)', '(+3)', '(+3)', '(=3)', '(+3)', '(+3)', '(=3)', '(+7)', '(+7)', '(+7)', '(+7)', '(+14)', '(+14)', '(+14)', '(+14)', 'Proptosis', 'Subject response in', 'Proptosis Non-responder', 'Proptosis Non-responder or Relapse', 'Relapse Only', 'Non-responder', 'Study HZNP-TEP-301', 'Only', 'Only', 'Informed Consent', 'X', 'Review inc/exc criteria', 'Weight 8', 'X9', 'X', 'X', 'X', 'X', 'Study drug infusion 10', 'X', 'Phone (email) contact for safety', '24 hours postdose 11', 'Investigator assessment of active', 'X', 'X', 'X', 'disease', 'Efficacy assessments', 'CAS', 'X', 'X', 'X', 'X', 'Clinical Measures of Severity', '- includes proptosis, diplopia,', 'X9', 'X', 'X', 'X', 'X', 'and motility restriction', 'Safety assessments', 'Pregnancy Test 12', 'x9', 'X', 'X', 'Physical exam 13', 'X9,13', 'X13', 'X13', 'Ophthalmic exam 14', 'X9', 'X', 'Vital Signs 15', 'X9', 'X', 'X', 'X', '12-Lead ECG', 'X9', 'X', 'Clinical laboratory tests 16', 'Chemistry (excl. glucose)', 'X9,17', 'X', 'X', 'X', 'X', 'Thyroid (FT3, FT4, TSH)', '18', 'X9', 'X', 'X', 'Hematology', 'X9', 'X', 'X', 'X', 'X', 'X', 'X', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 11 of 118']\n\n###\n\n", "completion": "END"}